Loading...

Next-generation Diagnostics Will Transform Preventive Healthcare

Published
09 Feb 25
Updated
20 Aug 25
AnalystConsensusTarget's Fair Value
US$6.00
42.0% undervalued intrinsic discount
20 Aug
US$3.48
Loading
1Y
-20.5%
7D
24.3%

Author's Valuation

US$6.0

42.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on31 Jul 25

With the consensus analyst price target and key valuation metrics such as the discount rate and future P/E ratio remaining effectively unchanged, analysts see little shift in OraSure Technologies’ fair value, which stays at $6.00. What's in the News Ron Zwanziger, supported by a Wall Street investor, made an unsolicited all-cash takeover offer for OraSure Technologies at $3.50-$4.00 per share, which the board rejected without discussions; this was Zwanziger’s second unsuccessful approach.

Shared on01 May 25
Fair value Increased 33%

Shared on23 Apr 25
Fair value Decreased 18%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 27%

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Increased 6.71%

AnalystConsensusTarget has decreased revenue growth from -17.0% to -5.5% and decreased future PE multiple from 32.2x to 23.1x.